English
Back
Open Account
2026 IPO bonanza! Over 90% of new stocks rose on their debut
牛牛新股君
joined discussion · Jun 15 08:58

New IPO News | "Peptide-based pharmaceutical company" Medica-B has launched its IPO, aiming to list on June 24, with a board lot subscription amount of HK$4,242.36

Futu News, June 15:$MICOT PHARMA-B (02335.HK)$An announcement was issued stating that the offering period will run from June 15 to June 18. The company plans to globally offer approximately 58,054,400 shares, with listing expected on June 24.
Futu News, June 15:$MICOT PHARMA-B (02335.HK)$An announcement was issued stating that the offering period will run from June 15 to June 18. The company plans to globally offer approximately 58,054,400 shares, with listing expected on June 24. Company Overview The company is committed to advancing peptide-based therapeutics as foundational treatments across multiple disease areas. Leveraging over a decade of experience in peptide drug research and development, the company has established a fully integrated platform to support the industrialization of dual-functional peptide-based drug candidates. As of the latest practicable date, the company has developed a pipeline of dual-functional peptides and innovative drug candidates, including: (i) its lead product MT1013, a peptide-based drug that simultaneously targets the CaSR and OGP receptors, primarily developed for the treatment of CKD-SHPT, with potential for further development in additional indications such as CKD-MBD with osteoporosis and non-dialysis-dependent CKD-SHPT; and (ii) three key products—XTL6001, MT1002, and MT200605—as well as other pipeline candidates. Financial Summary In 2024 and 2025, the company’s R&D expenses attributable to its lead product MT1013 amounted to RMB 66.7 million and RMB 84.4 million, respectively, representing 62.3% and 64...
Company Overview
The company is committed to advancing peptide-based therapeutics as foundational treatments across multiple disease areas. Leveraging over a decade of experience in peptide drug research and development, the company has established a fully integrated platform to support the industrialization of dual-functional peptide-based drug candidates.
As of the latest practicable date, the company has developed a pipeline of dual-functional peptides and innovative drug candidates, including: (i) its lead product MT1013, a peptide-based drug that simultaneously targets the CaSR and OGP receptors, primarily developed for the treatment of CKD-SHPT, with potential for further development in additional indications such as CKD-MBD with osteoporosis and non-dialysis-dependent CKD-SHPT; and (ii) three key products—XTL6001, MT1002, and MT200605—as well as other pipeline candidates.
Financial Summary
In 2024 and 2025, the company’s R&D expenses attributable to its lead product MT1013 amounted to RMB 66.7 million and RMB 84.4 million, respectively, representing 62.3% and 64.9% of the company’s total R&D expenses for those years. The company’s total R&D expenses increased by 21.6%, from RMB 107.0 million in 2024 to RMB 130.1 million in 2025. The company reported net losses of RMB 156.8 million and RMB 184.9 million in 2024 and 2025, respectively.
Futu News, June 15:$MICOT PHARMA-B (02335.HK)$An announcement was issued stating that the offering period will run from June 15 to June 18. The company plans to globally offer approximately 58,054,400 shares, with listing expected on June 24. Company Overview The company is committed to advancing peptide-based therapeutics as foundational treatments across multiple disease areas. Leveraging over a decade of experience in peptide drug research and development, the company has established a fully integrated platform to support the industrialization of dual-functional peptide-based drug candidates. As of the latest practicable date, the company has developed a pipeline of dual-functional peptides and innovative drug candidates, including: (i) its lead product MT1013, a peptide-based drug that simultaneously targets the CaSR and OGP receptors, primarily developed for the treatment of CKD-SHPT, with potential for further development in additional indications such as CKD-MBD with osteoporosis and non-dialysis-dependent CKD-SHPT; and (ii) three key products—XTL6001, MT1002, and MT200605—as well as other pipeline candidates. Financial Summary In 2024 and 2025, the company’s R&D expenses attributable to its lead product MT1013 amounted to RMB 66.7 million and RMB 84.4 million, respectively, representing 62.3% and 64...
Use of Proceeds
Regarding the use of proceeds, MedKey Pharma-B expects the net proceeds from the global offering to be approximately HK$1.067 billion (assuming the over-allotment option is not exercised and based on the mid-point of the offer price range at HK$19.60 per share). According to the prospectus, MedKey Pharma intends to allocate the proceeds from the global offering as follows:
Approximately 39.1% will be used for ongoing and planned clinical trials and planned commercial launches of the company's core products; approximately 36.3% will be used for ongoing and planned clinical trials and planned commercial launches of the company's key products; approximately 15.0% will be used for ongoing and planned clinical trials and planned commercial launches of MT200605; approximately 14.6% will be allocated to research and development of the company’s other pipeline candidates and technology platforms; and approximately 10.0% will be used for working capital and general corporate purposes.
Further reading:MedKey Pharma-B Prospectus
The golden season for new stock subscriptions has arrived! Use Futu for new stock subscriptions—zero interest, zero handling fees, and zero cash subscription. Participants now have the chance to have their new stock subscription fees waived for a year.Come and experience it now >>
Futu News, June 15:$MICOT PHARMA-B (02335.HK)$An announcement was issued stating that the offering period will run from June 15 to June 18. The company plans to globally offer approximately 58,054,400 shares, with listing expected on June 24. Company Overview The company is committed to advancing peptide-based therapeutics as foundational treatments across multiple disease areas. Leveraging over a decade of experience in peptide drug research and development, the company has established a fully integrated platform to support the industrialization of dual-functional peptide-based drug candidates. As of the latest practicable date, the company has developed a pipeline of dual-functional peptides and innovative drug candidates, including: (i) its lead product MT1013, a peptide-based drug that simultaneously targets the CaSR and OGP receptors, primarily developed for the treatment of CKD-SHPT, with potential for further development in additional indications such as CKD-MBD with osteoporosis and non-dialysis-dependent CKD-SHPT; and (ii) three key products—XTL6001, MT1002, and MT200605—as well as other pipeline candidates. Financial Summary In 2024 and 2025, the company’s R&D expenses attributable to its lead product MT1013 amounted to RMB 66.7 million and RMB 84.4 million, respectively, representing 62.3% and 64...
Editor/Vincent
Risk Disclaimer: The above content only represents the author's view. It does not represent any position or investment advice of Futu. Futu makes no representation or warranty.Read more
Thumbs Up
5
41K Views
Report
Comments
Write a Comment...
5
7